BASILE, DEBORA
 Distribuzione geografica
Continente #
NA - Nord America 1.117
AS - Asia 175
EU - Europa 163
AF - Africa 2
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.460
Nazione #
US - Stati Uniti d'America 1.114
SG - Singapore 87
IT - Italia 60
CN - Cina 47
UA - Ucraina 23
IE - Irlanda 22
VN - Vietnam 22
DE - Germania 20
IN - India 10
BE - Belgio 8
SE - Svezia 7
GB - Regno Unito 6
IR - Iran 6
CZ - Repubblica Ceca 5
FR - Francia 4
RU - Federazione Russa 4
CA - Canada 3
FI - Finlandia 2
HK - Hong Kong 2
CL - Cile 1
EC - Ecuador 1
EG - Egitto 1
EU - Europa 1
NL - Olanda 1
RO - Romania 1
TG - Togo 1
TR - Turchia 1
Totale 1.460
Città #
Fairfield 156
Chandler 147
Ashburn 116
Singapore 82
Woodbridge 63
Ann Arbor 57
Seattle 57
Houston 52
Wilmington 47
Cambridge 40
Beijing 28
Boardman 28
New York 25
Princeton 24
Dong Ket 22
Dublin 22
Martignacco 20
Dearborn 17
San Diego 11
Washington 11
Jacksonville 10
Brussels 8
Ogden 8
Udine 7
Ardabil 5
Bologna 5
Leawood 5
Los Angeles 5
Norwalk 5
Brno 4
Dallas 4
Jinan 4
Munich 4
Redmond 4
Caserta 3
Des Moines 3
Milan 3
Nanjing 3
Toronto 3
Augusta 2
Clifton 2
Edinburgh 2
Helsinki 2
Hong Kong 2
Phoenix 2
San Mateo 2
Wenzhou 2
Asti 1
Bangalore 1
Boston 1
Cairo 1
Catania 1
Chengdu 1
Duncan 1
Florence 1
Fuzhou 1
Grafing 1
Guayaquil 1
Hefei 1
Hyderabad 1
Izmir 1
Kunming 1
Langfang 1
Lomé 1
Lviv 1
Mortegliano 1
Moscow 1
Nanchang 1
Naples 1
Paris 1
Partanna 1
Prague 1
Redwood City 1
Romans 1
Rutigliano 1
San Francisco 1
Santa Clara 1
Shenzhen 1
Trento 1
Trieste 1
Tuenno 1
Wuhan 1
Totale 1.169
Nome #
Characterizing metastatic HER2-positive gastric cancer at the CDH1 haplotype 146
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 109
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 101
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 100
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 93
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside 88
Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma 85
Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey 70
Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival 67
Sarcopenia: looking to muscle mass to better manage pancreatic cancer patients 64
Small luminal-like breast cancer: determinants of adjuvant chemotherapy use 64
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer 64
Time to surgery after neoadjuvant chemotherapy for early breast cancer 53
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis 49
Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application 48
Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients 42
Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study 42
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer 40
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study 37
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer 36
First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study 33
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study 32
Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice 29
How I treat stage II colon cancer patients 28
State-of-the-art of monoclonal antibodies for the treatment of gastric cancer 14
The potential of retinoic acid receptors as prognostic biomarkers and therapeutic targets in gastric cancer 6
Totale 1.540
Categoria #
all - tutte 7.270
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.270


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020280 0 0 0 0 28 40 32 48 60 29 32 11
2020/2021334 18 9 24 51 32 20 12 44 8 27 38 51
2021/2022230 26 24 3 7 10 3 16 8 1 25 82 25
2022/2023298 25 39 8 28 35 58 1 28 50 4 12 10
2023/2024179 20 5 12 11 22 67 0 7 15 6 0 14
2024/2025131 13 30 15 35 38 0 0 0 0 0 0 0
Totale 1.540